Apex Capital Management’s United Therapeutics UTHR Stock Holding History

Apex Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$22.3M	Buy	199,892 +2,498	+1%	+$316K	0.49%	70
2015 Q4	$30.9M	Buy	197,394 +476	+0.2%	+$69.3K	0.69%	59
2015 Q3	$25.8M	Buy	196,918 +7,558	+4%	+$1.21M	0.58%	66
2015 Q2	$32.9M	Buy	189,360 +9,234	+5%	+$1.66M	0.7%	62
2015 Q1	$31.1M	Buy	180,126 +9,097	+5%	+$1.39M	0.73%	58
2014 Q4	$22.1M	Buy	171,029 +7,793	+5%	+$1M	0.59%	68
2014 Q3	$21M	Buy	163,236 +8,856	+6%	+$913K	0.63%	65
2014 Q2	$13.7M	Buy	154,380 +15,532	+11%	+$1.49M	0.42%	74
2014 Q1	$13.1M	Sell	138,848 -2,047	-1%	-$209K	0.46%	70
2013 Q4	$15.9M	Sell	140,895 -141,868	-50%	-$12.8M	0.6%	63
2013 Q3	$22.3M	Buy	282,763 +16,180	+6%	+$1.18M	0.98%	47
2013 Q2	$17.5M	Buy	+266,583	New	+$17.2M	0.85%	51

Other funds holding UTHR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Apex Capital Management's UTHR Position: Q1 2016 in Review

Apex Capital Management increased its United Therapeutics (UTHR) stake by 1.3% in Q1 2016, buying an estimated $316K and bringing the position to 199,892 shares worth $22.3M. The position accounts for 0.49% of the portfolio, ranked #70.

Apex Capital Management first reported a position in UTHR in Q2 2013 and has held it in 12 quarters since. The position peaked at $32.9M in Q2 2015. 399 funds tracked by Wall St. Rank hold UTHR as of Q1 2016.

Apex Capital Management held 199,892 shares of United Therapeutics worth $22.3M as of Q1 2016.
Apex Capital Management bought 2,498 United Therapeutics shares in Q1 2016, an estimated $316K.
United Therapeutics made up 0.49% of Apex Capital Management's portfolio in Q1 2016, its #70 holding.
Apex Capital Management first reported a position in United Therapeutics in Q2 2013 and has held it in 12 quarters since.
Apex Capital Management's United Therapeutics position peaked at $32.9M in Q2 2015.
399 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2016.

Based on Apex Capital Management's 13F filing for Q1 2016, filed 27 Apr 2016.